![](/img/cover-not-exists.png)
An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer
A. Araújo, B. Parente, R. Sotto-Mayor, E. Teixeira, T. Almodôvar, F. Barata, H. Queiroga, C. Pereira, H. Pereira, F. Negreiro, C. SilvaVolume:
14
Year:
2008
DOI:
10.1016/s2173-5115(08)70309-9
File:
PDF, 288 KB
2008